Assembly Biosciences Expands ABI-6250 Clinical Program into Cholestatic Liver Diseases, Targeting Phase 2 in Q1 2027
ASMB has more than doubled off its 52-week low of $13.13.
Summary
Assembly Biosciences is expanding its ABI-6250 clinical program into cholestatic liver diseases, including Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). A Phase 2 study for these new indications is anticipated to start in Q1 2027. This move significantly broadens the potential market for ABI-6250, particularly in PSC where no approved treatments currently exist, addressing a substantial unmet medical need. The company recently held a constructive pre-IND meeting with the FDA regarding this expansion. This pipeline development adds long-term value following recent Q1 results that showed a widened net loss.
At the time of this announcement, ASMB was trading at $26.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $421.2M. The 52-week trading range was $13.13 to $39.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.